{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:15:25Z","timestamp":1788221725668,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210126, JP25fk0310545, JP24fk0210121, JP25fk0210142, JP25fk0310551, JP25fk0210123, JP25fk0310535, JP25fk0210157, JP25fk0310543, JP25fk0210172, JP25fk0210174, and JP25fk0210143"],"award-info":[{"award-number":["JP25fk0210126, JP25fk0310545, JP24fk0210121, JP25fk0210142, JP25fk0310551, JP25fk0210123, JP25fk0310535, JP25fk0210157, JP25fk0310543, JP25fk0210172, JP25fk0210174, and JP25fk0210143"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early decline in HBsAg levels during nucleos(t)ide-analog (NA) therapy predicts subsequent HBsAg loss, but stratification tools are limited. We assessed whether a novel baseline HBV biomarker\u2014the HBsAg glycan-isomer (HBsAgGi)\u2014predicts 12-month HBsAg decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed genotype C chronic hepatitis B patients who initiated entecavir, tenofovir-disoproxil-fumarate, or tenofovir-alafenamide and had serum available for HBsAgGi measurement. Early decliners were defined as those with \u2265\u20090.10 log10 IU\/mL HBsAg reduction after 1 year. Baseline clinical and virological parameters were compared between decliners and non-decliners and within HBsAg\u2009&lt;\u20093,000 and \u2265\u20093,000 IU\/mL strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 201 screened individuals, 106 had samples for HBsAgGi testing. In this cohort, HBsAg levels continued to fall annually over 5 years in early decliners, whereas non-decliners showed almost no long-term HBsAg reduction. In univariate analyses, higher baseline HBsAg, HBV DNA, HBeAg-positivity, and HBcrAg were associated with 1-year HBsAg decline, whereas HBsAgGi was not; none remained significant in multivariable models. However, among patients with baseline HBsAg\u2009&lt;\u20093,000 IU\/mL, HBsAgGi alone differentiated decliners from non-decliners. After adjustment for baseline HBsAg and HBcrAg, lower HBsAgGi remained independently associated with \u2265\u20090.10 log10 IU\/mL HBsAg decline at 1 year. In patients with baseline HBsAg\u2009\u2265\u20093,000 IU\/mL, decliners had higher rates of HBeAg positivity and higher baseline HBsAg and HBcrAg. Traditional HBV markers were tightly correlated, whereas HBsAgGi showed only weak-to-modest correlations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline HBsAgGi adds prognostic value in patients with low HBsAg, identifying those more likely to achieve on-therapy HBsAg decline and potentially informing selection for intensified or combination HBV therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03227-w","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:16:02Z","timestamp":1781856962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Daisuke","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yasuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Meno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Kohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1186\/s12889-024-20462-4","volume":"24","author":"J Li","year":"2024","unstructured":"Li J, Gao Z, Bai H, Wang W, Li Y, Lian J, Li Y, Feng Y, Wang S. Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021. BMC Public Health. 2024;24:2936.","journal-title":"BMC Public Health"},{"key":"3227_CR2","doi-asserted-by":"publisher","unstructured":"Lazarevic I, Banko A, Miljanovic D, Cupic M. Hepatitis B surface antigen isoforms: their clinical implications, utilisation in diagnosis, prevention and new antiviral strategies. Pathogens. 2024;13. https:\/\/doi.org\/10.3390\/pathogens13010046.","DOI":"10.3390\/pathogens13010046"},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"ofae699","DOI":"10.1093\/ofid\/ofae699","volume":"11","author":"WF Hsu","year":"2024","unstructured":"Hsu WF, Chen CF, Lai HC, Su WP, Wang HW, Chen SH, Huang GT, Peng CY. Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B. Open Forum Infect Dis. 2024;11:ofae699.","journal-title":"Open Forum Infect Dis"},{"key":"3227_CR4","doi-asserted-by":"publisher","first-page":"42879","DOI":"10.1038\/srep42879","volume":"7","author":"CY Peng","year":"2017","unstructured":"Peng CY, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH. Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. Sci Rep. 2017;7:42879.","journal-title":"Sci Rep"},{"key":"3227_CR5","doi-asserted-by":"publisher","first-page":"e0188303","DOI":"10.1371\/journal.pone.0188303","volume":"12","author":"T Broquetas","year":"2017","unstructured":"Broquetas T, Garcia-Retortillo M, Hernandez JJ, Puigvehi M, Canete N, Coll S, Cabrero B, Gimenez MD, Sola R, Carrion JA. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLoS ONE. 2017;12:e0188303.","journal-title":"PLoS ONE"},{"key":"3227_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jvh.13869","volume":"30","author":"T Okumura","year":"2023","unstructured":"Okumura T, Joshita S, Iwadare T, Wakabayashi SI, Kobayashi H, Yamashita Y, Sugiura A, Kimura T, Umemura T. Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients. J Viral Hepat. 2023;30:731\u20139.","journal-title":"J Viral Hepat"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"106077","DOI":"10.1016\/j.antiviral.2025.106077","volume":"234","author":"B Yao","year":"2025","unstructured":"Yao B, Xu Q, Yamada Y, Angata K, Zhang Y, Narimatsu H, Yu D, Zhang X. Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy. Antiviral Res. 2025;234:106077.","journal-title":"Antiviral Res"},{"key":"3227_CR8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/hepr.14076","volume":"54","author":"Y Ikeda","year":"2024","unstructured":"Ikeda Y, Murata A, Nago H, Yamaguchi M, Om R, Terai Y, Kita Y, Sato S, Sato S, Shimada Y, Genda T. Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B. Hepatol Res. 2024;54:888\u201398.","journal-title":"Hepatol Res"},{"key":"3227_CR9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med. 2022;387:1957\u201368.","journal-title":"N Engl J Med"},{"key":"3227_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/13543784.2023.2277389","volume":"32","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs. 2023;32:971\u201383.","journal-title":"Expert Opin Investig Drugs"},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","volume":"82","author":"M Buti","year":"2025","unstructured":"Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, Chak E, Coffin CS, Fujiwara K, Gankina N, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82:222\u201334.","journal-title":"J Hepatol"},{"key":"3227_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hep.26376","volume":"58","author":"WK Seto","year":"2013","unstructured":"Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923\u201331.","journal-title":"Hepatology"},{"key":"3227_CR13","doi-asserted-by":"publisher","first-page":"e28452","DOI":"10.1002\/jmv.28452","volume":"95","author":"G Suda","year":"2023","unstructured":"Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, et al. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J Med Virol. 2023;95:e28452.","journal-title":"J Med Virol"},{"key":"3227_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2017.04.008","volume":"67","author":"N Kawagishi","year":"2017","unstructured":"Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, et al. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. J Hepatol. 2017;67:1106\u20138.","journal-title":"J Hepatol"},{"key":"3227_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jvh.12737","volume":"24","author":"N Kawagishi","year":"2017","unstructured":"Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M, et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24:1098\u2013106.","journal-title":"J Viral Hepat"},{"key":"3227_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","volume":"56","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168\u201380.","journal-title":"J Gastroenterol"},{"key":"3227_CR17","doi-asserted-by":"publisher","first-page":"106715","DOI":"10.1016\/j.jinf.2026.106715","volume":"92","author":"G Suda","year":"2026","unstructured":"Suda G, Ohara M, Baba M, Yamamoto Y, Yoshida S, Fu Q, Yang Z, Hosono H, Yokoyama D, Kitano S, et al. Tenofovir alafenamide prevents HBV reactivation in anticancer\/immunosuppression: 24-month multicentre prospective study. J Infect. 2026;92:106715.","journal-title":"J Infect"},{"key":"3227_CR18","doi-asserted-by":"publisher","first-page":"130020","DOI":"10.1016\/j.bbagen.2021.130020","volume":"1866","author":"K Angata","year":"2022","unstructured":"Angata K, Wagatsuma T, Togayachi A, Sato T, Sogabe M, Tajiri K, Ozawa T, Nagashima I, Shimizu H, Iijima S, et al. O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection. Biochim Biophys Acta Gen Subj. 2022;1866:130020.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"3227_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.16659","volume":"55","author":"A Vittal","year":"2022","unstructured":"Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, Ghany MG. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55:8\u201325.","journal-title":"Aliment Pharmacol Ther"},{"key":"3227_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361\u201370.","journal-title":"J Hepatol"},{"key":"3227_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","volume":"75","author":"MA Meier","year":"2021","unstructured":"Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol. 2021;75:840\u20137.","journal-title":"J Hepatol"},{"key":"3227_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12876-022-02352-4","volume":"22","author":"A Murata","year":"2022","unstructured":"Murata A, Angata K, Sogabe M, Sato S, Ichida T, Narimatsu H, Genda T. Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy. BMC Gastroenterol. 2022;22:270.","journal-title":"BMC Gastroenterol"},{"key":"3227_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.13564","volume":"38","author":"WF Hsu","year":"2018","unstructured":"Hsu WF, Chen CF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Wang HW, Huang GT, Peng CY. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Int. 2018;38:627\u201335.","journal-title":"Liver Int"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03227-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03227-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03227-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:46:31Z","timestamp":1788219991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03227-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03227-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hokkaido University Hospital (IRB no. 018\u2009\u2212\u20090008). Written informed consent was obtained from all the participants before enrolment. All authors had full access to the study data and reviewed and approved the final manuscript.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"205"}}